Tristan Jervis’ Post

CYTOMOS' TRANSFORMATIVE CELL ANALYSIS TECHNOLOGY Dr Lindsay Fraser - Cytomos' Chief Scientific Officer - delivered a great presentation on Cytomos' groundbreaking AuraCyt™️ cell analysis technology at the BIA’s 2023 BioProcessUK Dragon’s Den session held on 30 November.   AuraCyt™️ is securing leading industry recognition as a technological innovation that provides information on cell properties that no other process analytical technology (PAT) can. The capability to collect a multitude of data that measures the intrinsic properties of individual cells in real-time, and to obtain a unique profile for subsequent downstream analysis and characterisation, is set to radically change the way that processes are monitored, whilst transforming velocity in biopharmaceutical R&D and fundamentally changing bioprocess PAT adaptation.   The fast and scalable AuraCyt™️ platform closely monitors a broad range of individual cell features simultaneously, to provide label-free, unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications. AuraCyt™️ can save and optimise batches, addressing pressing industry needs for smarter, less labour-intensive, and more automated processes capable of driving down biomanufacturing costs and realising scale-out in the manufacture of personalised, regenerative medicines.   The AuraCyt™️ platform improves the pace and accuracy of single cell analysis. The ground-breaking technology harnesses the power of dielectric spectroscopy and Cytomos’ proprietary silicon chip sensors to enable researchers and scientists across the life science industry to generate unique fingerprints to characterise cells without the requirement for labels. The technology has the potential to be incorporated in-line, allowing real-time monitoring of cell manufacturing events and predicting manufacturing success. AuraCyt™️ is a compatible asset that is usable both alongside flow cytometry technologies or on its own.